Tonix Pharmaceuticals Holding, a clinical-stage biopharmaceutical company, announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic.
Swiss pharmaceutical firm Novartis has announced that its Sandoz division will provide a portfolio of 15 not-for-profit generic and over-the-counter (OTC) medicines to developing countries to treat the patients with Covid-19 symptoms.
A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in Antiviral Research.
Roche and Blueprint Medicines have signed a global licensing and collaboration deal worth up to $1.7bn for the latter's pralsetinib, an investigational treatment for RET-altered cancers.
Merck, a leading science and technology company, opened its M Lab Collaboration Centre in Shanghai, the company's largest of nine centers worldwide.
Kymera Therapeutics announced the company has entered into a multi-program strategic collaboration with Sanofi to develop and commercialise first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases.
Major drugmaker Pfizer has committed $100m to the new Antimicrobial Resistance (AMR) Action Fund, which will support the development of new antibiotics due to increasing antibiotic-resistant infections.
Reliable Oxygen Measurements Continuous dissolved oxygen (DO) measurement is critical during fermentation and cell culture.
Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, announced it has raised $110 million in a Series B financing.
Goldfinch Bio has raised $100m in a Series B funding round for the discovery and development of precision drugs for the treatment of kidney diseases.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.